News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Top VIVUS, Inc. (VVUS) Shareholder Plans To Buy Company In $640 Million Deal


5/29/2014 7:32:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Vivus Inc's (VVUS.O) biggest shareholder said it was planning to buy the obesity drug maker in a deal valued at $640 million, the latest shareholder attempt to revive a company that has struggled to boost sales of its key drug. Aspen Investment Fund, which reported a 9.65 percent stake in Vivus on Wednesday, said it expects to submit its non-binding offer to the company by June 13. The investment fund did not disclose the terms of the offer. Vivus had a market value of about $482 million as of Tuesday's close and debt of about $269 million.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Seeking Alpha
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES